Floatz logo

Gic-1001

Colonic Disease

gicare Pharma Inc.Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Colonic Disease cohort.

Asset / SponsorPhaseRating
Ibrutinib
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2CCC
Pembrolizumab
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2CCC
GIC-1002
gicare Pharma Inc.
Phase 1CC
MACROGOLS
Eastern Mediterranean University
N/AD

Same molecule, other indications

Gic-1001 is also rated in:

PainDormant
B
Indicative ·
61 / 100
View asset →
Colonic DiseasesDormant
B
Indicative ·
57 / 100
View asset →
cancerDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →